Currently, the only drugs approved internationally for the antiviral treatment of chronic hepatitis B are interferon (including regular interferon and long-acting interferon) and nucleoside analogues (including lamivudine, adefovir, telbivudine, entecavir, etc.), and most of the drugs on the market that claim to have antiviral effects do not live up to their names. The current antiviral drugs can inhibit hepatitis B virus replication and improve liver function, and liver fibrosis may be reversed in some patients, but the majority of patients cannot be completely cleared of hepatitis B virus through treatment, that is, they cannot be completely turned negative. In fact, with the current state of technology, there is no drug that can completely remove the hepatitis B virus. If a patient pursues the so-called negative transformation therapy and has high expectations of antiviral drugs for hepatitis B, he will be easily deceived by false advertising, and the patient will be the ultimate victim. However, patients do not have to be pessimistic, relying on the available drugs to achieve the treatment goal of long-term control of viral replication and stopping the progression of liver disease is entirely achievable.